Prevalence and correlates of metabolic syndrome and its components in adults with psychotic disorders in Eldoret, Kenya.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
06
2020
accepted:
22
12
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
11
5
2021
Statut:
epublish
Résumé
A high prevalence of metabolic syndrome and its components in patients with psychotic disorders may increase the risk for cardiovascular diseases. Unfortunately, relatively little work in this field has emerged from low-resourced contexts. This study investigated the prevalence, correlates, and treatment patterns of metabolic disorders in patients with psychotic disorders in Western Kenya. 300 patients with psychosis and 300 controls were recruited at Moi Teaching and Referral Hospital in Eldoret, Kenya. Data on demographic characteristics, weight, height, abdominal circumference, blood pressure, blood glucose, lipid profile, and treatments were collected. Categorical and continuous data were compared between the patient and control groups using Pearson's chi-squared tests and t-tests, respectively. Variables found to be significantly different between these groups were included in logistic regression models to determine potential predictors of metabolic syndrome. Compared to controls, patients with psychosis were found to have a higher mean random blood glucose [5.23 vs 4.79, p = 0.003], higher body mass index [5.23 vs 4.79, p = 0.001], higher triglycerides [1.98 vs 1.56, p<0.001], larger waist circumference [89.23 vs 86.39, p = 0.009] and lower high density lipoprotein [1.22 vs 1.32, p<0.001]. The odds of developing metabolic syndrome were increased with age [OR = 1.05, CI: 1.02-1.07] and presence of a psychotic disorder [OR = 2.09 [CI 1.23-3.55]; and were reduced with female gender [OR 0.41, CI 0.25-0.67], among those who were never married [OR 0.52, CI 0.28-0.94] and among the widowed/separated/ divorced marital status [OR 0.38, CI 0.17-0.81]. While the majority of patients received treatment with olanzapine, there was no association between olanzapine use and metabolic syndrome and its components. More than half of the patients in this study sample were not receiving treatment for the various components of metabolic syndrome. In the study setting of Eldoret, metabolic syndrome and its components were more prevalent among patients with psychotic disorders than in controls; and a clear treatment gap for these disorders was evident. There is a need for efforts to ensure adequate screening and treatment for these physical disorders in resource-limited settings.
Sections du résumé
BACKGROUND
A high prevalence of metabolic syndrome and its components in patients with psychotic disorders may increase the risk for cardiovascular diseases. Unfortunately, relatively little work in this field has emerged from low-resourced contexts. This study investigated the prevalence, correlates, and treatment patterns of metabolic disorders in patients with psychotic disorders in Western Kenya.
METHODS
300 patients with psychosis and 300 controls were recruited at Moi Teaching and Referral Hospital in Eldoret, Kenya. Data on demographic characteristics, weight, height, abdominal circumference, blood pressure, blood glucose, lipid profile, and treatments were collected. Categorical and continuous data were compared between the patient and control groups using Pearson's chi-squared tests and t-tests, respectively. Variables found to be significantly different between these groups were included in logistic regression models to determine potential predictors of metabolic syndrome.
RESULTS
Compared to controls, patients with psychosis were found to have a higher mean random blood glucose [5.23 vs 4.79, p = 0.003], higher body mass index [5.23 vs 4.79, p = 0.001], higher triglycerides [1.98 vs 1.56, p<0.001], larger waist circumference [89.23 vs 86.39, p = 0.009] and lower high density lipoprotein [1.22 vs 1.32, p<0.001]. The odds of developing metabolic syndrome were increased with age [OR = 1.05, CI: 1.02-1.07] and presence of a psychotic disorder [OR = 2.09 [CI 1.23-3.55]; and were reduced with female gender [OR 0.41, CI 0.25-0.67], among those who were never married [OR 0.52, CI 0.28-0.94] and among the widowed/separated/ divorced marital status [OR 0.38, CI 0.17-0.81]. While the majority of patients received treatment with olanzapine, there was no association between olanzapine use and metabolic syndrome and its components. More than half of the patients in this study sample were not receiving treatment for the various components of metabolic syndrome.
CONCLUSION
In the study setting of Eldoret, metabolic syndrome and its components were more prevalent among patients with psychotic disorders than in controls; and a clear treatment gap for these disorders was evident. There is a need for efforts to ensure adequate screening and treatment for these physical disorders in resource-limited settings.
Identifiants
pubmed: 33428652
doi: 10.1371/journal.pone.0245086
pii: PONE-D-20-18075
pmc: PMC7799838
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245086Déclaration de conflit d'intérêts
The authors declare no conflicting interest.
Références
Mol Metab. 2018 Sep;15:35-44
pubmed: 29706320
J Am Geriatr Soc. 2000 Sep;48(9):1111-6
pubmed: 10983912
Vasc Health Risk Manag. 2008;4(1):123-30
pubmed: 18629376
Gen Hosp Psychiatry. 2017 Mar - Apr;45:62-69
pubmed: 28274341
World Psychiatry. 2011 Jun;10(2):138-51
pubmed: 21633691
Schizophr Bull. 2013 Mar;39(2):306-18
pubmed: 22207632
J Natl Med Assoc. 2002 Oct;94(10 Suppl):1-26
pubmed: 12401060
BMC Public Health. 2018 Nov 7;18(Suppl 3):1219
pubmed: 30400858
Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):8-13
pubmed: 16001095
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Bipolar Disord. 2009 Sep;11(6):657-62
pubmed: 19689508
S Afr J Psychiatr. 2017 Apr 10;23:1089
pubmed: 30263202
Psychol Med. 2015;45(12):2619-29
pubmed: 25961431
Biomed Res Int. 2019 Nov 11;2019:1096201
pubmed: 31815121
Ann Hum Biol. 2012 Nov-Dec;39(6):530-3
pubmed: 22989146
Lancet Psychiatry. 2019 Aug;6(8):675-712
pubmed: 31324560
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Arch Gen Psychiatry. 2007 Aug;64(8):966-74
pubmed: 17679641
Eur Psychiatry. 2009 Sep;24(6):412-24
pubmed: 19682863
Psychiatry Res. 2019 May;275:238-246
pubmed: 30933701
PLoS One. 2016 Nov 17;11(11):e0166429
pubmed: 27855222
Am J Manag Care. 2017 May;23(5):304-308
pubmed: 28738686
Schizophr Res. 2010 Mar;117(1):75-82
pubmed: 20080392
PLoS One. 2017 Nov 29;12(11):e0188466
pubmed: 29186155
PLoS One. 2016 Feb 16;11(2):e0149209
pubmed: 26882230
J Clin Psychiatry. 2015 Sep;76(9):e1122-9
pubmed: 26455676
J Clin Psychiatry. 2007;68 Suppl 4:4-7
pubmed: 17539693
Postgrad Med J. 2007 Feb;83(976):109-14
pubmed: 17308214
Schizophr Bull. 2013 Mar;39(2):295-305
pubmed: 22927670
JAMA. 1996 May 22-29;275(20):1571-6
pubmed: 8622248
BMC Psychiatry. 2014 Aug 12;14:228
pubmed: 25113131
Afr J Psychiatry (Johannesbg). 2013 Nov 19;16(6):
pubmed: 24173635
Clin Obstet Gynecol. 2007 Dec;50(4):938-48
pubmed: 17982337
Pathology. 2019 Feb;51(2):131-141
pubmed: 30522787
Singapore Med J. 2018 Sep;59(9):465-471
pubmed: 29430576
BMC Geriatr. 2016 Jan 23;16:27
pubmed: 26803469
World J Diabetes. 2017 Aug 15;8(8):390-396
pubmed: 28861176
J Clin Psychopharmacol. 2011 Apr;31(2):154-9
pubmed: 21346617
Curr Neuropharmacol. 2017 Apr;15(3):424-433
pubmed: 28503115
BMC Public Health. 2018 Nov 7;18(Suppl 3):1215
pubmed: 30400865
Int J Epidemiol. 2011 Aug;40(4):885-901
pubmed: 21527446
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
BMJ Open. 2019 Feb 19;9(2):e025469
pubmed: 30782936
Annu Rev Nutr. 2017 Aug 21;37:225-245
pubmed: 28628359
Pharmacol Res. 2015 Nov;101:74-85
pubmed: 26218604
Int J Prev Med. 2012 Aug;3(8):552-8
pubmed: 22973485
EBioMedicine. 2015 Oct 09;2(10):1259-61
pubmed: 26629498
Schizophr Res. 2015 Feb;161(2-3):465-70
pubmed: 25560938
PLoS One. 2014 Apr 24;9(4):e94112
pubmed: 24763306
Afr Health Sci. 2011 Sep;11(3):414-20
pubmed: 22275932
World Psychiatry. 2016 Jun;15(2):166-74
pubmed: 27265707
BMJ Open. 2013 Apr 17;3(4):
pubmed: 23599376
Eur J Clin Nutr. 2014 Oct;68(10):1101-6
pubmed: 24918120
Lancet Psychiatry. 2015 May;2(5):431-451
pubmed: 26360287
Oncotarget. 2017 Sep 2;8(43):73568-73578
pubmed: 29088727
Asian J Psychiatr. 2016 Feb;19:28-36
pubmed: 26957335